Brain cell injection could tame Drug-Resistant epilepsy
NCT ID NCT07572812
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new cell therapy called UX-GIP001 for adults with drug-resistant temporal lobe epilepsy. The treatment involves injecting special brain cells into the seizure area to calm overactive nerves. Only 12 people will take part, and the main goal is to check safety and see if seizures decrease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UX-GIP001 (human GABAergic interneuron progenitor cells)
What this could lead to
If successful, this could point toward a new treatment option for people with drug-resistant epilepsy, potentially reducing or stopping seizures.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so safety and effectiveness are not yet proven. The cell injection into the brain carries surgical risks, and participants may need lifelong immunosuppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Contact
-
West China School of Medicine and West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Contact